Symbols

NERV

Minerva·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 1

Bearish signal 2

Ample Liquidity

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About NERV

Minerva Neurosciences, Inc.

A clinical-stage biopharmaceutical company focused on the therapies to treat central nervous system disorders

Industry

Pharmaceutical

Established Date

04/23/2007

Listing Date

07/01/2014

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.minervaneurosciences.com

Security Type

Common stock

Office address

1500 District Avenue, Burlington, MA 01803

Business

Introduction

Minerva Neurosciences, Inc., was incorporated under the laws of Delaware on April 23, 2007 in the name of Cyrenaic Pharmaceuticals, Inc. In November 2013, it merged with Sonkei Pharmaceuticals Ltd and the combined company was renamed Minerva Neurosciences Ltd. As a result of the merger, or the Sonkei merger, the company has the right to develop, sell and import MIN-101 and MIN -117 worldwide, excluding most of Asia under the rights under the license agreement with Mitsubishi Tanabe Pharma. The Company further expanded its product candidate portfolio in February 2014 by acquiring a stake in Mind-NRG SA (or Mind-NRG), which has the exclusive right to develop and commercialize MIN-301, or Mind-NRG acquisition. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing a portfolio of product candidates to treat patients with central nervous system (or CNS) diseases. The Company's lead product candidates are MIN-101, which is developing a therapeutic compound for the treatment of schizophrenia, and MIN-117, which is developing a pain treatment compound (or MDD) for the treatment of major depressive disorder.

Company Financials

EPS

NERV has released its 2025 Q3 earnings. EPS was reported at -0.36, versus the expected -0.35, missing expectations. The chart below visualizes how NERV has performed over recent quarters, highlighting trends in earnings surprises.